Lisa Simunovic

Suggest Changes
Learn More
BACKGROUND AND PURPOSE The intention-to-treat analysis of data from the placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found 80 mg atorvastatin per(More)
OBJECTIVE To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major(More)
  • 1